X
Total 959151 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Paravermic Lobule VIII | ILX:0108522 | 5 | FDI Lab - SciCrunch.org | 06/23/2020 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Paravermis of the anterior lobe of the cerebellum | ILX:0108523 | 6 | FDI Lab - SciCrunch.org | 06/23/2020 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Paravermis of the posterior lobe of the cerebellum | ILX:0108524 | 6 | FDI Lab - SciCrunch.org | 06/23/2020 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Paravermis parts of the cerebellar cortex | 'Paravermis parts of the cerebellar cortex' is a regional part of cerebellar cortex. It is part of the cerebellum intermediate zone. | ILX:0108525 | 7 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parcellation scheme | Set of parcels occupying part or all of an anatomical entity that has been delineated using a common approach or set of criteria, often in a single study. A parcellation scheme for any given individual entity may include gaps, transitional zones, or regions of uncertainty. A parcellation scheme derived from a set of individuals registered to a common target (atlas) may be probabilistic and include overlap of parcels in regions that reflect individual variability or imperfections in alignment. | ILX:0108526 | 5 | FDI Lab - SciCrunch.org | 01/17/2023 | ASH | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parcellation scheme parcel | Regions delineated in a particular parcellation scheme by either manual or automated tracing. | ILX:0108527 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parencephalon | Synonym for thalamus (Nebenhirn in German, originally; His, 1893). | ILX:0108528 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parental behavior | ILX:0108529 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Paresis | A general term referring to a mild to moderate degree of muscular weakness, occasionally used as a synonym for PARALYSIS (severe or complete loss of motor function). In the older literature, paresis often referred specifically to paretic neurosyphilis (see NEUROSYPHILIS). "General paresis" and "general paralysis" may still carry that connotation. Bilateral lower extremity paresis is referred to as PARAPARESIS (MeSH). | ILX:0108530 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Pargyline | A monoamine oxidase inhibitor with antihypertensive properties. (PubChem) Pharmacology: Pargyline is a monoamine oxidase B (MAO-B) inhibitor with antihypertensive properties. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis. Mechanism of action: Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Monoamine Oxidase Inhibitors | ILX:0108531 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Paricalcitol | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Pharmacology: Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin and from dietary intake. Vitamin D requires two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol (1,25(OH)2 D3), is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis.1 Decreased levels of 1,25(OH)2 D3 have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH)2 D3 and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy. An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A at concentrations up to 50 nM (21 ng/mL). Mechanism of action: Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion. Drug type: Approved. Investigational. Small Molecule. Drug category: | ILX:0108532 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Parietal cortex | Gray matter of the parietal region of the neocortex, located in the parietal lobe of gyrencephalic animals. It is continuous anteriorly with the frontal cortex, posteriorly with the occipital cortex and medially with the insular cortex and with the temporal cortex on the posterior/inferior border. | ILX:0108533 | 11 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parietal lobe | Upper central part of the cerebral hemisphere. (MSH) | ILX:0108534 | 11 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parietal operculum | The parietal operculum, forming the superior bank of the sylvian fissure, as studied in the cat, contains the secondary somatosensory representation, 'S-II', and a second somatotopic representation (parietal ventral, or PV). Anatomically, primate S-II receives inputs from area 3 and area 1, and projects to PV and area 7. PV has projections to area 5 and premotor areas. [WP,unvetted]. | ILX:0108535 | 9 | FDI Lab - SciCrunch.org | 06/23/2020 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parieto-occipital sulcus | Only a small part of the Parietooccipital Fissure (or parieto-occipital sulcus) is seen on the lateral surface of the hemisphere, its chief part being on the medial surface. The lateral part of the parietooccipital fissure (Fig. 726) is situated about 5 cm. in front of the occipital pole of the hemisphere, and measures about 1.25 cm. in length. The medial part of the parietooccipital fissure (Fig. 727) runs downward and forward as a deep cleft on the medial surface of the hemisphere, and joins the calcarine fissure below and behind the posterior end of the corpus callosum. In most cases it contains a submerged gyrus. [WP,unvetted]. | ILX:0108536 | 11 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parkin | A cytoplasmic neuronal protein containing two ring-finger domains and a ubiquitin-like dmain at its amino terminus. | ILX:0108537 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parkin Mutant Drosophila | These flies exhibit a mutation in the protein parkin. Loss of function in parkin results in the accumulation of toxic substrates. This causes locomotive defects, dopaminergic neuron degeneration, mitochondrial dysfunction, and sensitivity to oxidative stress. Physically, Parkin mutants are smaller, show locomotive dysfunction, sterile, and have a decreased lifespan. Parkin mutant drosophila exhibit many of the same symptoms as Parkinson's disease and are used in the laboratory to study the disease. | ILX:0108538 | 5 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Parkinsons disease | * A disease characterized as a progressive motor disability manifested by tremors, shaking, muscular rigidity, and lack of postural reflexes. (PSY) * A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) (MSH) * progressive, degenerative disorder of the nervous system characterized by tremors, rigidity, bradykinesia, postural instability, and gait abnormalities; caused by a loss of neurons and a decrease of dopamine in the basal ganglia. (CSP) | ILX:0108539 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Parnell's mustached bat | ILX:0108540 | 8 | FDI Lab - SciCrunch.org | 10/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb | |
| Paromomycin | An oligosaccharide antibiotic produced by various streptomyces. (PubChem) Pharmacology: Paromomycin is a broad spectrum antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin. Mechanism of action: Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Drug type: Approved. Investigational. Small Molecule. Drug category: Amebicides. Anti-Bacterial Agents. Antibacterial Agents | ILX:0108541 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X